Drug Profile
Apadamtase alfa - Takeda
Alternative Names: ADAMTS13, recombinant-krhn - Takeda; ADZYNMA; BAX-930; Cinaxadamtase alfa; rADAMTS-13; Recombinant ADAMTS13; Recombinant-A disintegrin and mellatoproteinase with thrombospondin type-1 motifs-13; SHP-655; TAK 755Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Kaketsuken
- Developer Takeda
- Class Antithrombotics; Disintegrins; Enzymes; Metalloproteases; Recombinant proteins
- Mechanism of Action ADAMTS13 protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Thrombotic thrombocytopenic purpura
- Phase I Vaso-occlusive crisis
Most Recent Events
- 26 Mar 2024 Registered for Thrombotic thrombocytopenic purpura (In adolescents, In children, In the elderly, In adults) in Japan (IV)
- 01 Feb 2024 Apadamtase alfa is still in phase-I trial for Vaso-occlusive-crisis in USA (IV, Infusion) (Takeda pipeline; February 2024)
- 09 Dec 2023 Adverse events and pharmacokinetics data from a phase-I RAISE-UP clinical trial in Vaso-occlusive crisis related to sickle cell anaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)